Segments - Schedule of Research and Development Expenses (Details) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2026 |
Sep. 30, 2025 |
Sep. 30, 2026 |
Sep. 30, 2025 |
|
| Segment Reporting [Line Items] | ||||
| Stock-based compensation expense | $ 5,220 | $ 3,153 | $ 14,100 | $ 9,113 |
| Reportable Segment | ||||
| Segment Reporting [Line Items] | ||||
| Nonclinical expenses | 385 | 184 | 1,025 | 445 |
| Clinical expenses | 2,220 | 7,250 | 11,564 | 18,315 |
| CMC expenses | 7,736 | 2,556 | 16,930 | 7,802 |
| License and milestone expenses | 0 | 0 | 10,000 | 0 |
| Salaries, benefits and related costs | 2,825 | 2,383 | 8,040 | 6,414 |
| Stock-based compensation expense | 1,791 | 1,189 | 4,714 | 3,606 |
| Other | 89 | 59 | 239 | 235 |
| Research and development expense | $ 15,046 | $ 13,621 | $ 52,512 | $ 36,817 |
| X | ||||||||||
- Definition Chemistry, Manufacturing And Control Expenses No definition available.
|
| X | ||||||||||
- Definition Clinical Expenses No definition available.
|
| X | ||||||||||
- Definition License And Milestone Expenses No definition available.
|
| X | ||||||||||
- Definition Nonclinical Expenses No definition available.
|
| X | ||||||||||
- Definition Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|